Is this your firm? Get featured or correct your listing →
Strategy
Recent changes
- Oct 16, 2026Oct 16, 2026Invested in Estuary Biotherapeutics (Series A, $93M) FierceBiotech
- Sep 6, 2026Sep 6, 2026Stages updated: Pre-IPO, Public deeptrackcapital.com
- Sep 5, 2026Sep 5, 2026Sectors updated: Biotechnology deeptrackcapital.com
Portfolio
3 totalRecent Investment Activity
1Track record: led 0 and participated in 1 of 1 tracked venture round · 1 in the last 12 months
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Estuary Biotherapeutics | Series A | Participated | $93M | — | RA CapitalLeadunverifiedDeep Track CapitalunverifiedGoogle Ventures (GV)unverifiedBiogen New VenturesUPMC EnterprisesPivotal bioVenture PartnersNational Kidney Foundation Innovation Fund+1 more | FierceBiotech |
Co-Investors
12Similar Firms
overlapping sector, stage or regionLatest Pulse
- Oct 16, 2026Estuary Biotherapeutics Launches With $103M For Kidney Gene TherapyEstuary Biotherapeutics emerged from stealth with $103 million, including a $93 million Series A led by RA Capital, to advance gene therapies for a common inherited kidney disease.→
- Sep 3, 2026Superluminal Raises $60M for AI-Designed Obesity PillThe Boston biotech's Series B, backed by Nvidia and Eli Lilly among others, funds Phase 1 trials of an oral MC4R agonist for rare genetic obesity designed by its de novo drug-discovery AI platform.→
- Aug 5, 2026Goldman-Backed Attovia Prices IPO, Lists on NasdaqAttovia Therapeutics priced its IPO at $17/share, raising roughly $212.5M, and began trading on Nasdaq today under ATTO -- another test of whether biotech's IPO window is genuinely reopening.→
- Jul 29, 2026Goldman-Backed Attovia Seeks $212.5M in Biotech IPOAttovia Therapeutics is seeking up to $212.5 million in a US IPO, offering 12.5 million shares at $15-$17 each, backed by Goldman Sachs Alternatives, Deep Track Capital, Frazier Life Sciences, and venBio.→
Deep Track Capital FAQ
What companies has Deep Track Capital invested in?
Deep Track Capital's portfolio includes Estuary Biotherapeutics, Attovia Therapeutics, Triveni Bio.
Who does Deep Track Capital co-invest with most?
In the rounds Value Add tracks, Deep Track Capital most often invests alongside Ascenta Capital (1 shared deal), Atlas Venture (1 shared deal), Cormorant Asset Management (1 shared deal), EcoR1 Capital (1 shared deal), Fidelity Investments (1 shared deal).
Sources & methodologyshow
- FierceBiotechmajor outlet1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.